Anne-Kathrin Stoller to Become New CEO at Bachem
Bubendorf, Switzerland--(Newsfile Corp. - October 31, 2025) - Ad hoc announcement pursuant to Art. 53 LR Anne-Kathrin Stoller to become new CEO at Bachem Bachem (SIX: BANB) announced today that its Board of Directors has appointed Anne-Kathrin Stoller, currently Head of Bachem Americas and previously the company's long-standing Chief Marketing Officer (CMO), as its new CEO, effective January 1, 2026. She succeeds Thomas Meier, wh
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-31 2:23 AM EDT | Bachem Holding AG
Republic Technologies Provides Corporate Updates for Q3 and Outlooks for Q4
Vancouver, British Columbia--(Newsfile Corp. - October 31, 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (the "Company" or "Republic") is pleased to provide this comprehensive news release outlining recent management updates, corporate developments, and business strategies for Q2 and Q3 2025. Management Update At the Company's Annual General and Special Meeting held on August 9, 2025, Republic announced the appointment of
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Republic Technologies gibt Unternehmensupdates für Q3 und Ausblick auf Q4 bekannt
Vancouver, British Columbia--(Newsfile Corp. - Freitag, 31. Oktober 2025) - Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (WKN: A41AYF) (das "Unternehmen" oder "Republic") freut sich, diese umfassende Pressemitteilung zu veröffentlichen, die aktuelle Management-Updates, Unternehmensentwicklungen und Geschäftsstrategien für das zweite und dritte Quartal 2025 zusammenfasst. Management-Update Auf der Jahres- und Sonderhauptversammlung des Unternehmen
Technology, Pharmaceuticals, Health
2025-10-31 2:00 AM EDT | Republic Technologies Inc.
Hemostemix's Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, today announced major progress in Flori
Biotechnology, Pharmaceuticals, Health
2025-10-30 11:29 AM EDT | Hemostemix Inc.
Herbal Dispatch Brings on Industry Veteran as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leader in cannabis distribution, is pleased to welcome Jay Wilgar, a 20-year veteran in startup management and business growth, to its team as a Strategic Advisor to the management team. Mr. Wilgar is the former CEO and Chairman of Newstrike Brands Ltd.—one of Canada's first licensed cannabis p
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-10-30 9:00 AM EDT | Herbal Dispatch Inc.
BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pione
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:30 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:00 AM EDT | PreveCeutical Medical Inc.
Quantum BioPharma Ltd. Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareh
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-29 9:00 PM EDT | Quantum BioPharma Ltd.
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce a one-hour educa
Biotechnology, Pharmaceuticals, Health
2025-10-28 3:44 PM EDT | Hemostemix Inc.
Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain(TM) Manufacturer-to-Patient Blockchain-Enabled Tracking & Dispensing Platform for Prescription Drug Market
Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (NASDAQ: DVLT) ("DataVault"), a pioneering technology company leading the way in AI data experie
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-10-27 9:42 AM EDT | Wellgistics Health
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon initiative, Beyond Type Run. Through this partnership, TempraMed joins Beyond Type 1 in empowering 55 inspiring
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-27 7:00 AM EDT | TempraMed Technologies Ltd
Telescope Announces Debt Settlement Transaction
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries, is pleased to announce that it has entered into agreements to settle certain outstanding indebtedness through the issuance of 689,654 common shares (each, a "Share") of the Company (the "Debt Settlement"). Purs
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-10-23 2:16 PM EDT | Telescope Innovations Corp.
The Gourmet Gifts Expands 2025 Corporate & Holiday Gifting Collection
Toronto, Ontario--(Newsfile Corp. - October 23, 2025) - The Gourmet Gifts, a trusted Canadian luxury gifting firm, today released its 2025 Holiday Collection. With its premium, thoughtfully curated gift baskets and hassle-free delivery, the company is further establishing itself among corporate customers as well as individual consumers. "We
Internet Technology, Pharmaceuticals, Publishing / Informational Services, Health
2025-10-23 10:04 AM EDT | BrandingEx Solutions Pvt Ltd.
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA
Biotechnology, Pharmaceuticals, Health
2025-10-23 3:15 AM EDT | Defence Therapeutics Inc.
Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 202
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-23 1:01 AM EDT | Bachem Holding AG
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has
Biotechnology, Pharmaceuticals, Health
2025-10-22 10:04 AM EDT | Hemostemix Inc.
Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform
Rockville, Maryland--(Newsfile Corp. - October 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has entered into a binding term sheet with 1542770 BC Ltd. ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies. Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule's as
2025-10-21 4:05 PM EDT | Shuttle Pharmaceuticals Holdings Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purcha
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-21 7:00 AM EDT | TempraMed Technologies Ltd